Society recognizes distinguished Canadians who have made remarkable contributions to their academic fields and public life
Two faculty members at The Neuro (Montreal Neurological Institute-Hospital) have been inducted into The Royal Society of Canada (RSC), recognizing their contributions to our understanding of neuroscience and the human brain.
A look at the latest ALS research and clinical care at The Neuro
Amyotrophic lateral sclerosis (ALS) is a terrible disease with no known cure. Research at The Montreal Neurological Institute and Hospital (The Neuro) is uncovering data that could help find effective treatments for ALS.
The Neuro has launched Neuro XXceptional - an exciting new year-long video series featuring women who tell us what drove them to become scientists and clinicians, and what they love about their work. At The Neuro, these exceptional professionals are improving the lives of patients, helping us understand how the brain works and how to treat neurological disease.
McGill University researchers have discovered a mechanism through which mitochondria, the energy factory of our body’s cells, play a role in preventing cells from dying when the cells are deprived of nutrients – a finding that points to a potential target for next-generation cancer drugs.
The research, published in Molecular Cell, builds on previous work by McGill professor Nahum Sonenberg, one of the senior authors of the new study.
ALS takes away the patient’s motor functions one at a time, and the progress of finding effective drugs to counter its insidious effects has been slow. June is ALS Month, a good time to update the public on the latest developments in ALS research taking place at The Neuro.
The Montreal Neurological Institute and Hospital (The Neuro) is recognized as a leading Canadian centre for research into amyotrophic lateral sclerosis (ALS) as well as for its care of ALS patients.
Research and clinical care complement each other at The Neuro
February 28th was Rare Diseases Day, an opportunity to recognize a class of disease that is often overlooked. In the past five years, the Montreal Neurological Institute and Hospital (The Neuro) has made the study and treatment of rare diseases a major priority, hiring new specialists and support staff and coordinating activity under a new research group.
A team of scientists led by Dr. Michel Desjardins from the University of Montreal and Dr. Heidi McBride from the Montreal Neurological Institute and Hospital (MNI) at McGill University have discovered that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease.
Using both cellular and mouse models, the team has shown that proteins produced by the two genes, known as PINK1 and Parkin, are required to prevent cells from being detected and attacked by the immune system.
The Neuro is recognized as a major Canadian center for ALS research and patient care. During June, designated ALS Month, The Neuro redoubles its efforts to inform the public and the media about amyotrophic lateral sclerosis (ALS), and urges all to help support ALS research.
As a major Canadian centre for amyotrophic lateral sclerosis (ALS) research and treatment, the Montreal Neurological Institute and Hospital - The Neuro, invites the public and the media to learn more about the disease and current research and treatments, to donate money for ALS research and to wear the national emblem of ALS in Canada, the blue cornflower, during ALS Awareness Month in June.
